Cite
HARVARD Citation
Hiwase, D. et al. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia research. pp. 109-115. [Online].